Big Phar­ma heavy­weights seek tweaks to FDA's clin­i­cal out­come as­sess­ment guid­ance

Pfiz­er, GSK, Janssen, Re­gen­eron, Boehringer In­gel­heim and at least a half dozen oth­er com­pa­nies are call­ing on the FDA to pro­vide sig­nif­i­cant­ly more clar­i­ty in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER